How Acthar Gel became a $250,000 drug

Some drugs become famous because they cure something spectacular. Acthar Gel became famous because its price tag started acting like it had its own publicist. This is a medicine first approved in 1952, made from porcine pituitary extract, and used for infantile spasms plus a long list of inflammatory and autoimmune conditions. For decades, it was old, obscure, and cheap. Then it became one of the most expensive medicines in America. That did not happen because scientists suddenly discovered it could moonwalk across the immune system. It happened because of a perfect storm of monopoly power, regulatory history, aggressive pricing, strategic marketing, and a health care payment system that often notices the fire only after the house is already smoking.

Acthar Gel’s rise is one of the clearest modern examples of how a legacy drug can be transformed into a financial machine. The story has everything: an old FDA approval, orphan-drug economics, a blocked competitor, repeated price hikes, public payer exposure, legal settlements, and the kind of corporate language that makes normal humans want to lie down in a dark room. If you want to understand how an old drug became a quarter-million-dollar treatment, Acthar is practically the textbook case.

What Acthar Gel actually is

Acthar Gel, also called repository corticotropin injection, is not a shiny new biotech breakthrough fresh from a trillion-dollar research bunker. It is an old drug with a very old regulatory passport. The FDA labeling still traces its initial U.S. approval to 1952. Today, it is indicated as monotherapy for infantile spasms in children under age 2, for acute exacerbations of multiple sclerosis in adults, and for a range of other disorders in rheumatology, dermatology, ophthalmology, pulmonology, and nephrology.

That breadth is part of the plot. A product with many labeled uses can be positioned in multiple specialties, which means more prescribers, more reimbursement battles, and more room to argue that even a niche drug deserves premium pricing. In plain English, Acthar was not just a drug. It was a commercial platform wearing a lab coat.

From bargain-bin medicine to premium-priced product

The price story is where Acthar stops being merely interesting and becomes downright jaw-dropping. Congressional investigators found that after Questcor acquired the rights in 2001, the price climbed from about $40 a vial to more than $31,000. After Mallinckrodt bought Questcor in 2014, the price kept rising, eventually reaching $39,864 per vial by 2020. In 2025, the official posted list price for the 5 mL multi-dose vial reached $45,304.

That means Acthar did not become expensive in one cartoon-villain leap. It got there through repeated hikes, each one building on the last. This is how many extreme drug prices happen in the real world: not with one dramatic explosion, but with a staircase made of invoices.

Congressional investigators said internal company materials treated Acthar as a premium-priced asset with strong cash flow. The House staff report also described efforts to make the drug seem cheaper without truly lowering the price, including interest in smaller vials so executives could say the sticker looked lower. That is not the same as making treatment affordable. That is price optics, which is a polite way of saying, “Let’s move the furniture around and hope nobody notices the ceiling is still leaking.”

The acquisition logic was the business model

Mallinckrodt’s 2014 acquisition of Questcor was not a mystery box. Reuters reported at the time that Acthar was already priced at about $30,000 a vial and was expected to generate enormous sales. The House report later argued that Acthar’s already-high price was part of what made Questcor so attractive. In other words, this was not a case of a company buying a neglected drug and then accidentally discovering it could be sold like luxury real estate. The price was central to the appeal.

By the time the acquisition was complete, Acthar was no longer just an old hormone product. It was a revenue engine. Investigators later said Mallinckrodt generated nearly $6 billion in net Acthar sales from 2014 through 2019. When one old drug starts carrying that much financial weight, every pricing conversation suddenly gets very “strategic.”

Why competition never really arrived

Competition is usually the part of capitalism that is supposed to show up, stretch a little, and punch outrageous prices in the face. That did not work out here. In 2017, the FTC said Questcor and Mallinckrodt agreed to pay $100 million to settle charges that Questcor had illegally acquired rights to Synacthen Depot, a drug that threatened Acthar’s monopoly in the U.S. ACTH market. According to the FTC, that acquisition preserved Questcor’s monopoly and helped maintain extremely high prices for Acthar.

That matters because even a sky-high price can survive if there is no real substitute competing in the same lane. Acthar had the advantages of age, brand recognition, existing labeling, and a market structure that made it hard for competition to discipline the price. The result was a medicine that could behave less like a commodity and more like a gated community.

The orphan-drug halo helped too

Acthar’s most emotionally powerful use is infantile spasms, a rare and serious seizure disorder in babies. That indication gave the drug a rare-disease narrative, and congressional investigators said executives discussed aggressive pricing in connection with orphan-drug dynamics. Rare diseases do create real development challenges, and some high prices are defended on those grounds. But Acthar’s story is different because the drug itself was already ancient. This was not a startup clawing back R&D from years of risky science. It was a decades-old product enjoying modern specialty-drug pricing.

So how did it become a “$250,000 drug”?

Because the vial price and the treatment pattern can combine into numbers that look like typos. KFF Health News reported the case of a father whose child was prescribed six vials for a six-week course when the per-vial price was $39,864. Do the math and you get about $239,184. That is close enough to a quarter of a million dollars to make everyone in the room suddenly very interested in spreadsheets.

And that was before the newer list prices. In 2025, the official list price of a 5 mL vial was $45,304. Depending on dose, indication, and duration, repeated courses can push annual spending into the hundreds of thousands. OHSU researchers said a typical adult course could easily exceed $100,000 and that repeated therapy can add up to hundreds of thousands of dollars a year. They also noted that the average Medicare patient using Acthar cost about $318,000 annually.

So the title is not a gimmick. It reflects the real-world math of a drug whose per-vial price became so high that a modest number of vials could produce a house-sized bill.

Marketing, reimbursement, and the payer tug-of-war

High prices survive only if someone pays. In Acthar’s case, that “someone” was often Medicare, Medicaid, or private insurance plans fighting through prior authorization, appeals, and specialty-pharmacy rules. ProPublica reported that Medicare’s spending on Acthar jumped twentyfold from 2008 to 2012, reaching $141.5 million, with 2013 expected to go even higher. Later, STAT reported that Medicare spent more than $500 million on the drug in 2015 alone.

The legal fallout was not small. The DOJ announced in 2022 that Mallinckrodt agreed to pay $260 million to resolve allegations that it underpaid Medicaid rebates for Acthar and used a foundation as a conduit for illegal co-pay subsidies. In a related announcement, the government said Acthar’s price had gone from roughly $50 per vial in 2001 to $40,000 per vial. Separately, HHS-OIG summarized a 2019 resolution in which Questcor agreed to pay $15.4 million over allegations that it provided lavish dinners and entertainment to induce prescriptions.

Put all of that together and you get a revealing picture: price hikes alone did not make Acthar notorious. It was the combination of price, payer exposure, sales tactics, and government scrutiny that turned it into a symbol.

Did the clinical evidence justify the price?

This is where the story gets especially uncomfortable. OHSU researchers reviewing the evidence said the clinical benefit of Acthar appeared weak compared with much cheaper corticosteroids for many indications. Their review found little convincing evidence that the drug was clearly superior to low-cost alternatives in most of the settings where it was being used. That does not mean Acthar has zero role. It does mean the burden of proof should be high when a drug costs more than a luxury car per vial.

Infantile spasms is the strongest part of the case for Acthar, and even critics often treat that indication differently from the broader adult-use story. But beyond that niche, the evidence debate has been fierce for years. The problem is not simply that Acthar is expensive. The problem is that much of the medical and payer community has never been persuaded that its broad commercial success matched equally broad clinical value.

That gap between price and evidence is what makes the Acthar story so useful as a warning. A drug does not need universally loved clinical data to become commercially dominant. It needs enough regulatory legitimacy, enough specialty positioning, enough reimbursement traction, and enough insulation from competition. After that, the billing department can start doing CrossFit.

Why this happened in the American system

Acthar’s rise was not just about one company making aggressive choices. It was also about the structure of American drug pricing. The system tolerated a legacy drug with old approvals, limited head-to-head modern evidence, fragmented payer oversight, and delayed competition. Public programs ended up absorbing a large share of the cost. By the time policymakers, journalists, and watchdogs fully focused on the drug, billions had already moved through the pipeline.

This is also why Acthar keeps showing up in discussions about health care reform. It is an example that works on multiple levels: monopoly, reimbursement loopholes, legacy approvals, list-price inflation, specialty-pharmacy complexity, and the mismatch between what a drug costs and what many experts believe it delivers. If you wanted to invent a case study for a graduate seminar called “How Not to Design a Drug-Pricing System,” Acthar would demand its own week on the syllabus.

The bigger lesson behind the sticker shock

Acthar Gel became a quarter-million-dollar treatment not because a dazzling scientific breakthrough forced the market to bow in awe. It became that expensive because the market let it. A very old drug gained modern pricing power. A thin-competition environment protected it. A specialty-drug framework helped normalize it. Public and private payers struggled to contain it. And by the time the enforcement actions arrived, the product had already minted years of extraordinary revenue.

That is what makes the Acthar story linger. It reminds us that the price of a drug is not always a verdict on its novelty, its manufacturing complexity, or even its evidence base. Sometimes it is a verdict on who has leverage, who lacks alternatives, and how long a system can confuse price with value before somebody finally says, “Hold on, why does this invoice look like a mortgage?”

Experiences around the Acthar Gel story: what this looks like in real life

To really understand how Acthar Gel became a $250,000 drug, it helps to step away from the spreadsheets and look at the human experience around it. For families, the experience often starts with panic, not economics. A parent hears that a baby may need treatment for infantile spasms, or an adult hears that a neurologist or rheumatologist is considering Acthar after other therapies have failed. In that moment, nobody is thinking about rebate formulas or antitrust settlements. They are thinking, “Will this work, and how fast can we get it?” That urgency is powerful, and it gives an expensive drug a huge emotional advantage.

Then comes the second wave: insurance. Prior authorization, specialty pharmacies, benefits investigations, co-pay questions, appeals, denials, partial approvals, coverage exceptions. Families are suddenly forced to become amateur reimbursement lawyers while also trying to manage a frightening medical condition. When a six-vial course can flirt with a quarter-million dollars, every approval decision feels like a referendum on whether the system will help or simply shrug in corporate.

Doctors experience the drug differently. Some clinicians see Acthar as a niche rescue therapy when standard steroids fail or are poorly tolerated. Others see it as a symbol of everything that has gone sideways in specialty-drug pricing. Either way, prescribing it is rarely simple. The physician is not just choosing a treatment. They are stepping into a maze of payer rules, pharmacy logistics, and paperwork thick enough to stop a small door. Even when the doctor believes the drug might help, there is often an uneasy awareness that the cost will be shocking and the evidence outside select indications may be less than inspiring.

Pharmacists and payer teams have their own version of the experience, and it is every bit as exhausting. They see the claims, the utilization patterns, the sticker prices, and the budget impact in real time. A single Acthar approval can reshape a monthly drug-spend report. For public payers especially, that means taxpayer money is on the line. Every high-cost claim forces a deeper question: Is this truly the best option for this patient, or are we watching a legacy product use its market position to outrun common sense?

And then there is the broader public experience. Most people will never use Acthar, but they still pay for the system that allowed it to thrive. Premiums, taxes, Medicare spending, and employer health costs all absorb part of the shock. That is why Acthar resonates beyond the patients who receive it. It is not just a specialty-drug story. It is a mirror reflecting how the American health care system can take an old medicine and wrap it in enough pricing power, reimbursement complexity, and limited competition that it starts costing like a moon mission. The lived experience, in the end, is not just medical. It is financial, administrative, emotional, and political all at once.